Celltrion Gets Ready To Push Tocilizumab Into Phase III
Korean Company Offers Latest Details On Plans For Actemra/RoActemra Biosimilar
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.
You may also be interested in...
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.